Mind Medicine Stock Price, News & Analysis

Mind Medicine (NASDAQ: MNMD) announced management will present at four investor conferences in Nov–Dec 2025: Stifel Healthcare on Nov 12, 2025 at 1:20 PM ET (New York), Jefferies Global Healthcare on Nov 18, 2025 at 12:00 PM GMT (London), Evercore Healthcare fireside on Dec 2, 2025 at 12:30 PM ET (Coral Gables), and Piper Sandler fireside on Dec 3, 2025 at 3:00 PM ET (New York).

Each event will offer an audio webcast and replays will be available on MindMed’s Investor Relations website for up to 90 days after each presentation.

MindMed (NASDAQ: MNMD) announced inducement equity grants to three newly hired non‑executive employees, consisting of options to purchase an aggregate of 90,750 common shares with an effective grant date of November 3, 2025.

The options carry an exercise price equal to MindMed’s closing share price on the grant date, vest over four years with 25% vesting on the first anniversary and the remaining 75% vesting in substantially equal monthly installments over the following three years, subject to continued employment.

The awards were approved by the compensation committee on October 31, 2025 as material inducements under NASDAQ Rule 5635(c)(4) and were granted outside MindMed’s equity incentive plans.

Mind Medicine (NASDAQ: MNMD) closed an underwritten public offering of 21,131,250 common shares at $12.25 per share, including the underwriters’ full exercise of an option for an additional 2,756,250 shares.

The gross proceeds were approximately $259 million before underwriting discounts, commissions and offering expenses. The offering closed on October 31, 2025. MindMed intends to use net proceeds to fund research and development, working capital and general corporate purposes, and may use a portion to invest in or acquire complementary businesses or compounds, although it has no current plans or commitments for acquisitions.

Mind Medicine (NASDAQ: MNMD) will report Q3 2025 financial results on Thursday, November 6, 2025 and host a live webcast at 4:30 p.m. EST to discuss results and recent business updates for the quarter ended September 30, 2025.

Listeners can register for the live webcast and analysts can register for the Q&A via the company links. A replay will be available in the Investor Relations section at ir.mindmed.co and archived for at least 30 days. Participants are advised to join 15 minutes before the start time.

Mind Medicine (NASDAQ: MNMD) priced an underwritten public offering of 18,375,000 common shares at $12.25 per share, expected to raise approximately $225 million in gross proceeds. The underwriters have a 30-day option to purchase up to an additional 2,756,250 shares at the offering price.

All shares are being sold by MindMed, with net proceeds intended for research and development of product candidates, and for working capital and general corporate purposes; the company said it may use some proceeds for acquisitions but has no current plans. The offering is expected to close on or about October 31, 2025, subject to customary conditions.

Mind Medicine (NASDAQ: MNMD) announced on October 29, 2025 a proposed underwritten public offering of common shares and, for certain investors, pre-funded warrants to purchase common shares. The offering may include a 30-day underwriter option to buy additional common shares at the public offering price, less discounts and commissions.

MindMed said it intends to use net proceeds for research and development, working capital and general corporate purposes, and may invest in or acquire complementary businesses though it has no current plans or agreements for acquisitions. Securities are being offered under a shelf registration on Form S-3 (File No. 333-280548) that was filed June 28, 2024 and became effective upon filing; final terms will be in a prospectus supplement to be filed with the SEC.

MindMed (NASDAQ: MNMD) granted an inducement option to a newly hired non-executive employee on October 14, 2025. The option covers 28,000 common shares, with an exercise price equal to MindMed's closing share price on the grant date.

The option vests over four years: 25% at the first anniversary and the remaining 75% in substantially equal monthly increments over the next three years, subject to continued employment. The grant was approved by the Compensation Committee on October 7, 2025 and was issued outside MindMed's equity incentive plans as a material inducement under NASDAQ Rule 5635(c)(4).

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has issued inducement grants to three new non-executive employees. The grants consist of options to purchase 182,800 common shares with grant dates of September 15 and September 22, 2025.

The options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly increments over the following three years. The exercise price is set at the closing price of MindMed's shares on the respective grant dates. These grants were approved by MindMed's Compensation Committee on September 10, 2025, in compliance with NASDAQ Rule 5635(c)(4).

MindMed (NASDAQ: MNMD) presented significant findings from a cross-sectional retrospective study at Psych Congress 2025, analyzing over 75,000 respondents from the 2022 National Health and Wellness Survey. The study revealed alarming statistics about suicidal ideation (SI) in individuals with Generalized Anxiety Disorder (GAD).

Key findings include: 48% of severe GAD patients reported almost daily SI, 78% with moderate GAD and 91% with severe GAD reported SI within two weeks. The study also found that 65% of GAD patients reported major depressive disorder (MDD) symptoms. Among the general population, 28.4% of U.S. adults reported SI, with highest rates among men (33%), young adults aged 18-34 (47.5%), Hispanic individuals (47.6%), and students (42.9%).